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This article is a systematic review of the literature about the coexistence of cancer and 
autoimmune rheumatic diseases, their main associations, cancers and possible risk factors 
associated, with emphasis on existing population-based studies,   besides checking the 
relation of this occur with the use of the drugs used in the treatment of autoimmune dis-
eases. A search was conducted of scientific articles indexed in the Cochrane / BVS, Pubmed 
/ Medline and Scielo / Lilacs in the period from 2002 to 2012. Also consulted was the IB-
ICT (Brazilian digital library of theses and Masters), with descriptors in Portuguese and 
English for “Systemic sclerosis”, “Rheumatoid Arthritis”, “ Systemic Lupus Erythematosus” 
and “Sjögren’s syndrome”, correlating each one with the descriptor AND “neoplasms”. The 
results showed that in the database IBICT a thesis and a dissertation for the descriptor 
SLE met the inclusion criteria, none met RA  one thesis to SS. Lilacs in the database/Scielo 
found two articles on “Rheumatoid Arthritis” AND “neoplasms”. In Pubmed/Medline the 
inicial search resulted in 118 articles, and 41 were selected. The review noted the relation-
ship between cancer and autoimmune rheumatic diseases, as well as a risk factor for pro-
tection, although the pathophysiological mechanisms are not known.
© 2014 Elsevier Editora Ltda. All rights reserved.
☆ Study conducted at Universidade Federal da Paraíba (UFPB), João Pessoa, PB, Brazil.
* Corresponding author.
E-mail: alessabraz@gmail.com (A.S. Braz).
0482-5004/$ - see front matter. © 2014 Elsevier Editora Ltda. All rights reserved.
http://dx.doi.org/10.1016/j.rbre.2014.03.008
2255-5 21
132 R E V  B R A S  R E U M A T O L .  2 0 1 4 ; 5 4 ( 2 ) : 1 3 1 – 1 3 9
Incidência de neoplasias nas doenças reumatológicas autoimunes mais 
prevalentes: uma revisão sistemática
Palavras-chave:
Neoplasias
Lúpus eritematoso sistêmico
Artrite reumatoide
Síndrome de Sjögren 
Esclerose sistêmica
r e s u m o
O presente artigo é uma revisão sistemática da literatura que aborda a coexistência de 
neoplasias e doenças reumatológicas autoimunes, suas principais associações, tipos de 
cânceres e os possíveis fatores de riscos associados, com ênfase nos estudos de base po-
pulacional existentes, além de verificar a relação dessa ocorrência com o uso dos fármacos 
utilizados no tratamento de doenças autoimunes. Foi realizada uma busca de artigos cien-
tíficos indexados na Cochrane/BVS, Pubmed/Medline e Scielo/Lilacs no período de 2002 a 2012. 
Também foi consultada a IBICT (biblioteca digital brasileira de teses e mestrados), com os 
descritores em português e inglês para as palavras: “Esclerose sistêmica”, “Artrite reuma-
toide”, “Lúpus Eritematoso Sistêmico” e “Síndrome de Sjögren”, correlacionando cada um 
com o descritor AND “neoplasias”. Os resultados mostraram que, na base de dados IBICT, 
preencheram os critérios de inclusão uma tese e uma dissertação para o descritor LES, ne-
nhuma para AR e uma tese para SS. Na base de dados Lilacs/Scielo foram encontrados dois 
artigos sobre “Artrite Reumatoide” AND “neoplasias”. No Pubmed/Medline, a busca inicial 
resultou em 118 artigos; destes, preencheram os critérios e foram secionados 41 artigos. 
Esta revisão observou relação entre neoplasias e as doenças reumatológicas autoimunes, 
tanto como fator de risco quanto de proteção, embora os mecanismos fisiopatológicos não 
estejam totalmente elucidados.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
The coexistence of rheumatic diseases with malignancies of 
various origins has been reported in the literature. Neoplas-
tic changes can induce rheumatic paraneoplastic syndromes, 
which also may be  late complications of a rheumatic disease.1
Rheumatologic paraneoplastic syndromes may occur dur-
ing the course of neoplastic disease, manifesting simulta-
neously with the development of a neoplasia, may precede 
the diagnosis by several years or develop some time after a 
neoplasia diagnosis. It is often difficult to differentiate them 
from the idiopathic form and it is believed that the presence 
of such changes can be considered as predictor of malignancy 
and of adverse outcomes.2-5
According to Szekanecz,6 neoplasms differ from paraneo-
plastic syndromes due to the fact that the latter are not re-
lated to direct invasion of  the tumor or metastasis, but to a 
variety of biological mediators derived from it, such as hor-
mones, peptides, antibodies, cytotoxic lymphocytes and au-
tocrine and paracrine mediators.
Autoimmune rheumatic diseases are chronic diseases, 
more common in females. Among these, the most prevalent 
include rheumatoid arthritis (RA), systemic lupus erythema-
tosus (SLE), Sjögren's syndrome (SS) and systemic sclerosis 
(SSc).7,8 Such autoimmune disorders are associated with the 
activation of autoreactive T and B lymphocytes and with the 
release of proinflammatory cytokines that can possibly in-
crease the risk of cancer.9 Taking into account that autoim-
mune diseases are chronic disorders and prevalent in the 
population, one can expect that patients with such diseases 
are most likely to develop neoplasias.10
The participation of immunosuppressive drugs in the 
treatment of autoimmune rheumatic diseases has also 
been described in the pathogenesis of malignancy. The 
potential mechanisms described include interruption of 
immunological surveillance and destruction of malignant 
cells, increased susceptibility to contamination with onco-
genic infectious agents, for instance, viral agents, pharma-
cological effects of the alkylating agents or antimetabolites 
on deoxyribonucleic acid (DNA), and the specific effects on 
the immune system, which can increase or decrease the 
chances of a transformed cell to survive and proliferate.11
In the literature, data related to this topic is scarce, es-
pecially in Brazil. This paper aims to conduct a systematic 
review of literature on the subject, because of its impor-
tance in clinical practice, and verify the main associations 
between the most prevalent autoimmune rheumatic dis-
eases and the types of cancer present, in addition to ad-
dressing the possible implications of using drugs in these 
circumstances.
Methodology
Search criteria
For this study, a systematic review technique was chosen. 
The search for scientific articles indexed in Cochrane/VHL, 
Pubmed/Medline and SciELO/Lilacs databases from 2002 to 
2012.  The IBICT (Brazilian digital library of theses and Masters 
programs) was also consulted, using the descriptors in por-
tuguese and their corresponding in english: “Rheumatoid ar-
thritis”, “SLE”, “Systemic sclerosis” and “Sjögren's syndrome”, 
correlating each with the descriptor AND “neoplasms”.
Inclusion and exclusion criteria
Full articles published in english and portuguese from 2002 
to 2012,which addressed the neoplasia occurrence in the 
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above autoimmune rheumatic diseases were included in 
the study. Articles describing the association of cancer and 
the main drugs used in the treatment of these autoim-
mune rheumatic diseases (methotrexate, azathioprine, cy-
clophosphamide, and immunobiological agents) were also 
selected.
In the present review, case reports or articles that re-
lated neoplasms and dermatomyositis and/or polymyosi-
tis were not included to avoid confusion, since there is a 
strong association of these conditions with paraneoplastic 
syndromes. We also excluded studies associating the oc-
currence of neoplasms with vasculitis, due to important 
differences in the pathogenesis of these diseases with the 
autoimmune diseases selected, and also to the fact that 
these are uncommon syndromes, not meeting the purposes 
of this study.
Selection of studies
The analysis of titles and abstracts, according to the eligibil-
ity criteria, was performed by two independent reviewers. In 
cases of disagreement, they were analyzed by a third reviewer.
Presentation of results
After the election of articles, a reading and analysis of the as-
sociation among cancer and selected rheumatic diseases was 
made. Population studies were described according to the au-
thor, year, studied population, observation on the occurrence 
of neoplasia in patients with autoimmune diseases, main 
malignancies observed in each disease and standardized in-
cidence ratio in the 95% confidence interval (CI). of Studies 
relating the main drugs used in the therapy of these diseases 
and their possible associations with oncogenesis were also 
analyzed.
Results
In the IBICT database, the following results concerning the 
initial search were obtained: no thesis for “Systemic sclerosis" 
AND “neoplasms”, one thesis/dissertation on “Systemic scle-
rosis” AND “neoplasms”, one thesis on “rheumatoid arthritis” 
AND “neoplasms”, four theses/dissertations on “Systemic Lu-
pus Erythematosus” AND “neoplasms”, and also four theses 
for “Sjögren's syndrome” AND “neoplasms”. One thesis and 
one dissertation for the descriptor SLE, one dissertation for 
the descriptor LES, none for AR and one thesis for SS met the 
inclusion criteria. In the Lilacs/Scielo database, two articles 
were found for “Rheumatoid Arthritis” AND “neoplasms”, but 
only one of them approached the studied matter .
In Pubmed/Medline database, the initial search yielded 
118 articles. Reports of paraneoplastic syndromes and articles 
about cancer treatments in patients with the assessed rheu-
matic diseases were excluded from the study. Thus, we select-
ed 41 articles that met the inclusion criteria described above 
(Fig. 1). The articles obtained, organized by author and year, 
neoplasia and standardized incidence ratio (SIR) in the 95% 
confidence interval (CI) are shown in Table 1, and the main 
population studies by author and year are shown in Table 2.
Discussion
Systemic lupus erythematosus and neoplasia 
SLE is a heterogeneous systemic disease manifesting in mild, 
moderate or severe clinical form that can escalate with mul-
tiple organs and/or systems involvement. Due to the modern-
ization of its therapy and to the improvements in the prog-
nosis of the disease in general, the survival rates of patients 
increased and in consequence chronic organ damage and late 
complications (such as malignancy) became decisive for the 
morbidity and mortality of these patients.12
The common pathogenic pathways for LES and neoplasms 
have been described, and reinforced by the following con-
cepts: a high frequency of malignancies in patients with au-
toimmune diseases; neoplastic disorders in autoimmune dis-
eases may occur as paraneoplastic syndromes; and the fact 
that immunosuppressive therapy may increase the risk of 
Table 1 – Main cancers in each autoimmune disease and 
their standardized incidence ratio (SIR) in a confidence 
interval (CI) of 95%.
Autoimmune disease Standardized incidence ratio 
(SIR)/Confidence interval (CI) 
of 95%/References
Systemic lupus erythematosus 
General risk 1.2519 / 1.1523/1.1421
Blood cancer 2.7523
Non-Hodkgin’s lymphoma 2.8619/ 3.6423
Lung cancer 1.7319 /1.3723
Hepatobiliary cancer 2.623/ 2.721
Vulvovaginal cancer 3.2721
Prostate cancer 0.7222
Sjogren's syndrome 
Overall risk 3.2527
Non lymphoid overall risk 1.526
Lymphoma 37.526 / 48.127
Systemic sclerosis
Overall risk 1.533
Lung cancer 1.633
Blood cancer 2.533
Rheumatoid arthritis
Overall risk 1.0541
Blood cancer 2.7427
Non-Hodgkin’s lymphoma 3.5427
Lung cancer 1.6341
Colorectal cancer 0.7741
Breast cancer 0.8441
Fig. 1 – Algorithm of the methodology of selection of papers 
found in Pubmed/Medline. PNS, paraneoplastic syndromes.
 
118 articles related to the descriptors in the English language: neoplasia 
AND systemic lupus erythematosus; neoplasia AND systemic sclerosis; 
neoplasia AND rheumatoid arthritis; neoplasia AND Sjögren's syndrome.
77 articles did not meet the criteria for 
inclusion/exclusion: case reports, articles 
about PNS and specific treatment of 
cancer.
41 articles related to established 
criteria.
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malignancies occurrence.13 Added to this, in a recent publica-
tion the presence of antiphospholipid antibodies was consid-
ered a risk factor for the occurrence of thrombotic events and 
for the development of cancer.14
Regarding etiopathogeny, LES as well as various other ma-
lignancies have in common a genetic predisposition to envi-
ronmental factors (such as ultraviolet radiation, infection by 
viruses such as Epstein-Barr virus [EBV], smoking and obe-
sity), and hormonal changes related to these two conditions 
(prolactin, estrogen and growth hormones, among others).15
Disproportionate humoral responses are considered fun-
damental in the pathogenesis of systemic autoimmune dis-
eases such as SLE and SS. Among these, an abnormal regula-
tion of the cell cycle is observed, which interferes with cell 
proliferation, differentiation and  apoptosis, causing B cell 
longevity. In these processes, cytokines such as interleukin-6 
(IL-6), 10 (IL-10) and B-cell activating factor (BAFF) have played 
an important role.16,17
It is believed that because of chronic antigenic stimulation, 
B cells contribute to the increased circulating levels of BAFF, 
and the impaired autoregulation of these cytokines may trig-
ger a vicious cycle in which high levels of proliferation and 
induction of BAFF or its ligand enhance the activation of the 
humoral immune system. A similar pathogenic mechanism 
has been described in B-cells related malignancies.12,18 
For several authors, there has been an increased incidence 
of malignancies in patients with SLE.13,19-22
A population-based cohort evaluated 5,715 patients hos-
pitalized for SLE between 1964 and 1995, according to the 
National Swedish Cancer Registry. Altogether, 443 cases of 
malignancies were assessed. The overall risk was increased 
by 25% (Standardized incidence rate [SIR] = 1.25, CI 95% = 1.14-
1.37). Non-Hodgkin lymphoma risk increased almost three 
times (SIR = 2.86, CI 95% = 1.96-4.04), thus providing a greater 
incidence for neoplasia in patients with SLE. There was also 
an increased risk of lung (SIR = 1.73, CI 95% = 1.25-2.32) and 
squamous cell skin (SIR = 1.53, CI 95% = 0.98 -2.28) cancer, 
which was more pronounced in cases with more than 15 
years of follow-up.19
In 2006, Bernatsky et al. conducted an international mul-
ticenter study that included patients with SLE from 23 reg-
istered centers, to analyze the causes of mortality of this 
disease; a major cause analyzed was the presence of cancer. 
Patients at each center were linked to regional cancer regis-
tries that provided epidemiological data and 9,547 patients 
were observed for an average period of eight years. 
Within the observation time, 431 cases of cancer were 
registered. The data confirmed an increased risk of cancer 
among patients with SLE. For all cancers combined, the esti-
mated SIR was 1.15 (CI 95% = 1.05-1.27); for all hematological 
malignancies, 2.75 (95 % CI = 2.13-3,49), and for non-Hodgkin 
lymphoma, 3.64 (CI 95% CI = 2.63-4.93). The findings also sug-
gested an increased risk of lung (SIR = 1.37, CI 95% = 1.05-1.76) 
and hepatobiliary (SIR = 2.60, CI 95 % = 1.25-4,78) cancer.23
In another cohort including individuals with SLE from the 
state of California (USA) from 1991 to 2002, the risk of occur-
rence of malignancies was studied. From the 30,478 patients 
diagnosed with SLE, 1,273 had a form of cancer. The overall 
cancer risk was significantly elevated (SIR = 1.14, CI 95% = 
1.07-1.20). This study demonstrated an increased risk of ma-
lignancies of the genital tract, including vaginal and vulvar 
(SIR = 3.27, CI 95% = 2.41-4.31), as well as liver (SIR = 2.70, CI 
95% = 1.54-4.24) cancer.21
In 2011, Bernatsky et al. analyzed 6,068 men suffering from 
SLE. The development of prostate cancer in this sample was 
lower than expected for the general population, with an esti-
mated incidence rate for risk of prostate cancer development 
in this population of 0.72 (CI 95% = 0.57-89). Thus, according to 
the findings of this study, LES was a protective factor against 
this type of cancer. One of the hypotheses proposed to explain 
these results is the occurrence of low levels of adrenal hor-
mones in these patients.22
Sjögren's syndrome and neoplasia
Sjögren's syndrome (SS) is an autoimmune disease character-
ized by lymphocytic infiltration of exocrine glands and persis-
tent dysregulation of the immune system. SS is associated with 
a 44-fold risk increase for non-Hodgkin development, and Ma-
saki and Sugai24 in 2004 estimated in their review that about 5% 
of cases of primary SS could develop this complication.
Similarly to what occurs in SLE, in SS the participation of 
environmental factors (EBV, cytomegalovirus, retroviruses, 
hepatitis C virus or ultraviolet radiation) and the genetic pre-
disposition (histocompatibility antigen [HLA] of B8, DR2, DR3 
and DQ types) change of the immune system are described; 
particularly at populations of CD4+ T cells or humoral pro-
duction of  antibodies production (anti-SSA/Ro, anti-SSB/
La and anti-muscarinic receptor type 3 antibody), as well as 
cytokines present such as interferon-gamma. In some cases, 
Table 2 – Population studies according to author/
year/country and observations about emergence of 
malignancies in patients with autoimmune diseases.
Authors/year Population basis/year of 
research
Observation
Bjornadal et al., 
200220
5.715 LES patients; Sweden 
(1964-1995)
443 cases of 
neoplasia
Bernatsky et al., 
200623
9.547 LES patients; 
international multicentric 
(1970-2001)
431 cases of 
neoplasia 
observed; 114 
deaths
Parikh-Patel  
et al., 200821
30.478 LES patients; USA 
(1991-2002)
1.273 cases of 
neoplasia
Bernatsky et al., 
201122
6.068 men with LES; follow-
up for 6.3 years; Canada
Prostate cancer 
considered as 
a protective 
factor
Lazarus et al., 
200626
112 patients with SS; London 
(1979-2006)
25 cases of 
neoplasia
Zhang et al., 
201027
1.320 patients with SS; 
Peking (1990-2005)
Follow-up for 
4.4 years: 
29 cases of 
neoplasia
Olesen et al., 
201033
2.040 patients with SSc; 
Denmark (1977-2006)
Follow-up for 
6.4 years: 
222 cases of 
neoplasia.
Chen et al., 
201137
23.644 patients with RA; 
Taiwan (1996-2007)
935 cases of 
cancer
SLE, systemic erithematous lupus; SS, Sjögren syndrome; SSc, 
systemic sclerosis; RA, rheumatoid arthritis.
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monoclonal B-cell proliferation occurs and this may lead to 
lymphomas.18,25
In 2006, Lazarus et al.26 performed a retrospective analysis 
of 112 patients from the outpatient services at the University 
College London Hospital during 1979. The patients were fol-
lowed for a mean period of 10.8 years since the diagnosis of 
primary SS (pSS). The appearance of neoplasia was reported 
in 25 patients, with 11 cases of lymphoma (eight of muco-
sa-associated lymphoid tissue/MALT type, one well-differ-
entiatied high-grade non-Hodgkin lymphoma, and two with 
unknown subtypes). Therefore, a significantly increased inci-
dence of lymphoma in patients with pSS compared with the 
general population (SIR = 37.5, CI 95% = 20.7-67.6) was demon-
strated. For cancers not originated in the lymphoid tissue, the 
observed increase in incidence was small and not statistically 
significant (SIR = 1.5, CI 95% = 0.9-2.6).26
A retrospective analysis at Peking Union Medical College 
Hospital from 1990 to 2005 recruited 1,320 SS patients that 
were followed for a mean of 4.4 years. Among them, 29 pa-
tients (2.2%) developed neoplasms during follow-up. The total 
SIR and SIR value  for lymphomas were 3.25 and 48.1, respec-
tively. In this study, different types of malignancies were ob-
served: eight lymphomas, two myelomas and 19 solid tumors 
(invasive thymoma, breast cancer, lung cancer, gastrointes-
tinal adenocarcinoma, hepatoma, squamous cell carcinoma 
of the tongue, cervical cancer, renal cell carcinoma, thyroid 
carcinoma and mucoepidermoid carcinoma of the parotid 
gland). At the risk factor analysis, it was observed that hy-
perplasia of the parotid glands, monoclonal immunoglobulins 
and the presence of hypergammaglobulinemia were identi-
fied as the main mechanisms involved in the pathogenesis of 
SS, compared with neoplasias.27
Systemic sclerosis and neoplasia 
Systemic sclerosis (SSc) is a complex immune connective 
tissue disorder that leads to vascular damage and overpro-
duction of extracellular matrix via activated fibroblasts. Its 
pathogenesis involves the interaction between endothelial 
cells, lymphocytes, macrophages, fibroblasts and the activa-
tion of several cytokines and growth factors important in the 
development of fibrosis. Immunological reactions involved in 
SSc have been associated with the development of malignan-
cies, and high concentrations of pro-fibrotic cytokines such as 
transforming growth factor beta (TGF-β) were found in some 
types of cancer (breast, ovary and kidney).28,29
Another possible hypothesis for such association is the 
presence of SSc antigens expressed in tumoral cells. Most of 
SSc autoantigens are nucleolar and play a key role in ribo-
some synthesis and in mitogenesis. Probably these proteins 
are related to the rapid proliferation of malignant cells. Ge-
netic mutations or post-translational modifications can pro-
duce protein products with conformational changes that ac-
cumulate in malignant tissue and create new epitopes.30
The association between cancer and SSc with fibrotic lung 
involvement was first described in 1953.31 During 2005, Dan-
iels and Jett found an increased risk of lung cancer in patients 
with disorders associated with pulmonary fibrosis, including 
systemic scleroderma. In this scenario, the suggested patho-
genesis is that recurring injury and chronic inflammation re-
sult in genetic mutations and possible malignancy; however, 
this hypothesis needs further studying.32
Olesen et al.33 assessed patients with an initial diagnosis of 
SSc selected from the Danish National Registry that included 
inpatients and outpatients during the period from 1977 to 
2006. About 2,040 patients were evaluated and followed for 
a mean period of 6.4 years. Among these patients, 222 cancer 
cases were identified. The general SIR for cancer was 1.5 (CI 
95% = 1.3-1.7); for men, SIR = 2.2 (CI 95% = 1.7-2.8) and for 
women, SIR = 1.3 (CI 95% = 1.1-1.6). The most common cancers 
were lung (SIR = 1.6, CI 95% = 1.2-2.0) and hematologic (SIR = 
2.5, CI 95% = 1.5-4.0) cancer.33
Rheumatoid arthritis and neoplasia
Rheumatoid arthritis (RA) is a disease that affects primar-
ily joints and cartilage through the development of pannus, 
a product of inflammatory cells and cytokins that transform 
synoviocytes into locally invasive and destructive cells. Al-
though predominantly joint affecting, RA can evolve with ex-
tra-articular manifestations affecting the skin, vessels, heart, 
lungs and peripheral nerves, as well as a significant associa-
tion with focal and systemic malignancy.34
The possible mechanisms for the increased risk of hema-
tological cancers in this pathology include: persistent im-
mune stimulation (which can lead to clonal selection and 
predispose CD5+ B cells to malignant transformation), de-
creased number and function of suppressor T cells (including 
those directed against prooncogenic Epstein-Barr virus) and 
decreased activity of natural killer cells in the synovial fluid, 
tissue, blood and lymph.35
According to Askling et al.,36 who examined the risk of can-
cer in a cohort study comparing RA patients versus the gener-
al population, there was little evidence of an increased cancer 
risk for most types of non-hematological cancers, but there 
was a moderate increase in the risk of developing lung can-
cer. In contrast, this study showed an approximate two-fold 
higher risk of lymphoma in patients with RA compared to the 
general population. However, these authors stated that the 
determinants of this association between RA and lymphoma 
remain unknown.
A cohort evaluated the association between RA and ma-
lignancy in Asian populations. The study included 23,644 pa-
tients with RA who had no previous history of malignancies, 
obtained through National Health Insurance Administration 
of Taiwan database between 1996 and 2007. Among patients 
with RA, 935 cancer cases were observed. This group showed 
an increased risk, especially for hematological cancers (SIR = 
2.74, 95 % CI = 2.68-2.81). The relative risk of cancer was higher 
among young people. 
Most cases of cancer were detected at the first year after 
RA diagnosis. The relative risk for cancer decreased with an 
increasing duration of the study and between hematologi-
cal cancers, non-Hodgkin's lymphoma had the highest risk 
of development (SIR = 3.54, CI 95% = 3.45-3.63). Among solid 
tumors, the risk of kidney, vaginal and vulvar cancer were the 
greatest. A decreased risk of cervix and nonmelanoma skin 
cancer in patients with RA was also observed.37
Thompson, Rider and Poper (2011) conducted a meta-anal-
ysis on the risk of infection and malignancies in patients with 
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RA treated with anti-TNFα. Regarding the analysis for associ-
ation of malignancy, the survey of literature data from six ran-
domized clinical trials showed that malignancies occurred in 
19 of 2,183 patients (0.87%) who received at least one dose of a 
TNFα inhibitor, and in 10 of 1,236 patients (0.81%) in the con-
trol group. The risk of malignancy did not increase in patients 
treated with a TNFα inhibitor, compared to control patients 
treated with methotrexate (SIR = 1.08, CI 95% = 0.50-2.32).
The results of this meta-analysis provide continuous sup-
port to the existing data showing that the overall increased 
risk for malignancies was not observed with anti-TNFα.38
The study by Dixon et al.39 corroborated the hypothesis of 
a null association of cancer with the use of anti-TNFα, even 
in patients with a history of neoplasia. An analysis was con-
ducted on patients enrolled by the British Society of Rheu-
matology Biologics Registers (RSRBR) diagnosed with RA and 
who were starting an anti-TNFα drug as their first biological 
agent. Patients enrolled within six months after the start of 
biologic therapy were excluded. Rates of malignancy for 177 
patients treated with anti-TNFα and for 117 patients with ac-
tive RA treated with disease-modifying antirheumatic drugs 
(DMARDs) were compared, all of them with a history of prior 
malignancy.
The rates of malignancy incidence were of 25.3 events/1000 
person per year in anti-TNFα group and 38.3/1,000 person per 
year in the DMARD cohort, generating a relationship of age 
and standardized incidence ratio of 0.58 (95 % CI = 0.23-1.43) 
for the cohort using anti-TNFα versus DMARD’s. Of the pa-
tients previously afflicted with melanoma, 3 (18%) out of 17 
in the cohort of anti-TNFα developed a malignant event, com-
pared with 0 out of 10 in the DMARD cohort.39
According to the British Society for Rheumatology guide-
lines for the use of anti-TNFα, instruct that “caution should 
be exercised with the use of anti-TNFα therapies in patients 
with previous malignancy; however, the potential benefits of 
this treatment should be considered against the potential 
risk of recurrence of a particular malignancy. If the patient 
was recurrence free of any malignant tumor for the last 10 
years, there is no evidence of a contraindication to anti-
TNFα therapy.”40
Smitten et al. (2008)41 conducted a meta-analysis that eval-
uated 21 publications found on Medline from 1990 to 2007, 
from which 13 articles reported an increased SIR for general 
malignancies; 14 for lymphoma, 12 for lung cancer, 10 for 
colorectal cancer, and nine for breast cancer. Compared to the 
general population, global estimates suggest that RA patients 
have an increase of approximately twice the risk of lympho-
ma (SIR = 2.08, CI 95% = 1.80-2.39) and a higher risk of Hodg-
kin’s lymphoma as well as non-Hodgkin’s lymphoma. The 
risk of lung cancer also increased (SIR = 1.63, CI 95% = 1.43-
1.87). In contrast, a decreased risk was observed for colorectal 
(SIR = 0.77, CI 95% = 0.65-0.90) and breast (SIR = 0.84, CI 95% 
= 0.79 -0.90) cancer. For general malignancy, SIR rate was 1.05 
(CI 95% = 1.01-1.09).41
Therapy and the risk of malignancies
Besides pathogenic mechanisms that suggest an increased 
susceptibility of patients for cancer occurrence (impaired im-
mune surveillance and destruction of cancerous cells, pos-
sible association of infection and uncontrolled lymphocyte 
proliferation by oncogenes), the therapy used in autoimmune 
rheumatic diseases has been described as a potentially carci-
nogenic factor (Table 3).11
The principal DMARDs classes used in rheumatology and 
for the therapy of the above-mentioned diseases include im-
munosuppressive and/or alkylating agents. Among the im-
munosuppressive agents commonly used as DMARDs in au-
toimmune diseases, methotrexate (MTX) and azathioprine 
are the most commonly prescribed, and the development of 
malignancies associated with their long-term use has been 
previously studied.
MTX is a dihydrofolate reductase antagonist, when pres-
ent it inhibits DNA synthesis and inhibits the proliferation 
of B and T lymphocytes. In 1997, Bologna et al.42 analyzed the 
possible relationship of an increased incidence of tumors 
and treatment with MTX in patients with rheumatoid ar-
thritis. The study included 426 patients treated with MTX, 
from which eight cases of neoplasia were detected. In the 
other hand, in the control group with 420 patients who had 
never been treated with MTX, it was observed a develop-
ment of six cases of neoplasia. The authors concluded that 
there was no statistically significant difference between 
groups and that further studies were required, since the 
drug could be a precipitating factor for tumorigenesis in 
predisposed patients. 
According to Sobral (2006),43 neoplasias that requirse 
treatment with MTX  are rare.  However, Wolfe and Michaud 
(2004)44 and Franklin et al.45 have found a higher incidence of 
malignancies, particularly lymphomas, in RA patients treat-
ed with immunosuppressants. Although it is not possible to 
differentiate the cause, it is usually associated with intense 
lymphocytic inflammatory activity or the use of immunosup-
pressive drugs to control severe active disease.44,45
Azathioprine is an immunosuppressive antimetabolite 
that acts by inhibiting the biosynthesis of adenine and gua-
Table 3 – Medication and its possible oncogenic 
mechanism.
Drug Pathogenic paths
Methotrexate42 Antagonizes dihydrofolate reductase, 
inhibits DNA synthesis and 
proliferation of B and T cells
Exhibits no increased risk42
Azathioprine43.46 Inhibits the biosynthesis of adenine 
and guanine, interfering with cell 
multiplication
Inactivate body immunosurveillance.
Possible increased risk of 
lymphoproliferative disorders43,46
Cyclophosphamide43.46-48 Crosslinkage with DNA strands prevent 
replication
Increased risk of cervical intraepithelial 
neoplasm48
Biological agents50-54 Immunomodulation
Infliximab and adalimumab with an 
increased risk of cancer, especially 
lymphoma and rectal, breast and 
lung cancer51
Abatacept: no increased risk of 
malignancies was found53,54
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nine, interfering with cell multiplication. The risk for onco-
genesis is described as a limiting factor for its use on a large 
scale. The oncogenic risk is related to the inactivation of body 
immunosurveillance, combined with immunological changes 
in patients with autoimmune diseases. The main risk is as-
sociated with lymphoproliferative diseases and premalignant 
cervical atypia.43,46
Alkylating agents have as primary target the cell cycle; 
these pharmaceuticals interrupt or disturb key steps in 
cell proliferation and consequently lead to replicating cells 
death.43 According to Almeida et al.,46 alkylating agents cross-
link with DNA strands preventing its replication and thereby 
destroying the cells at rest or in active cell division. Conse-
quently, cytotoxicity occurs by cross-reactivity with the other 
DNA strand. 
In autoimmune rheumatic diseases, the most widely used 
alkylating agent is cyclophosphamide. Silva et al.47 reported 
that the treatment with alkylating agents may induce second-
ary hematologic malignancies, including acute leukemias. In 
patients with SLE, Ognenovski et al.48 reported a higher inci-
dence of cervical intraepithelial neoplasias in patients taking 
cyclophosphamide.
In this context, biological agents are mainly used in RA 
therapy. These include antagonists of tumor necrosis fac-
tor α (anti-TNF-α), interleukin-1 receptor, IL-6 receptor and 
B cell surface markers (anti-CD20) as well as  lymphocyte 
costimulation modulators.49 In Brazil there are five types of 
anti-TNF-α agents: Etanercept, Infliximab, Adalimumab, Cer-
tolizumab pegol and Golimumab. The latter two were recently 
released for use in this country.
In a meta-analysis published in 2012, Solomon, Mercer and 
Kavanaugh50 analyzed publications related to the use of bio-
logical agents and on the development of malignancies. 
The drugs studied were abatacept, atanercept, adalimum-
ab, infliximab, anakinra and rituximab in the treatment of RA. 
In most studies analyzed, an increased incidence of cancer in 
patients treated with anti-TNF agents was not demonstrated. 
However, in a meta-analysis of clinical trials Bongartz et al.51 
have demonstrated an association between infliximab and 
adalimumab with increased risk of cancer, especially lym-
phoma, colorectal, breast and lung types.
It has been shown that IL-6 is involved in the pathophysi-
ology and prognosis of prostate cancer, hence anti-IL-6, a bio-
logical agent, appears to be involved in its prevention. Howev-
er, there are no studies on the use of this drug as a protective 
factor for this neoplasia yet.52
Simon et al.53 catalogued a total of 4,134 RA patients treat-
ed with abatacept evaluated in seven trials, and 41,529 RA 
patients treated with non-biologic DMARDs in five observa-
tional cohorts. From the patients treated with abatacept, 51 
malignancies were detected, however these findings were not 
higher than the expected from the five cohorts of RA control 
cases. The values of SIR comparing RA patients against the 
general population were consistent with those reported in 
the literature. The overall incidence of malignancies (exclud-
ing nonmelanoma skin cancer), and of breast cancer, colorec-
tal cancer, lung cancer and lymphoma in the abatacept group 
was the expected in a comparable population with RA. These 
data suggest that there are no new safety signs regarding ma-
lignancies; therefore, this issue should be monitored.
Corroborating the above hypothesis, Genovesel et al.54 
studied 1,167 RA patients treated with abatacept for a period 
of five years, without identifying an increased SIR among us-
ers of this agent.
Final considerations
The development of this review revealed a shortage of ar-
ticles addressing the subject, in particular Brazilian studies, 
as well as epidemiological studies about the topic. Despite 
this limitation, this study found a relationship between neo-
plasias and the autoimmune rheumatic diseases analyzed, 
both as risk factors and as protective factors, although the 
pathophysiological mechanisms involved are not well un-
derstood. Hematologic cancers were observed in all condi-
tions studied, especially lymphoma. In the particularities of 
each disease, lung cancer was strongly associated with SLE, 
SSc and RA, followed by colorectal and liver cancers. SLE rep-
resented a possible protective factor against prostate cancer, 
which was explained due to hormonal aspects of the disease 
in SLE patients.
The principal neoplasias were analyzed according to 
their incidence in each group of rheumatic diseases, and 
the carcinogenic potential of drugs used in the therapy of 
rheumatic diseases cannot be ignored, especially azathio-
prine and cyclophosphamide in RA and/or SLE patients. The 
authors also highlight the lack of Brazilian epidemiological 
studies addressing this association.
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